Charmian A Quigley
Charmian Quigley is an Australian paediatric endocrinologist who has had extensive involvement in Turner syndrome (TS) research for over 25 years. Charmian trained in Sydney before completing a molecular biology fellowship in the USA, where she worked from 1989 until returning to Australia in 2015. Charmian’s achievements in TS research began in 1996 with her key role on the team that secured the US Food and Drug Administration approval for growth hormone treatment in girls with TS. Thereafter, she expanded her work in design, management and analysis of Phase 2, 3 and 4 clinical trials, including the award-winning ‘Toddler Turner’ trial. This landmark study, developed in collaboration with Professor Marsha Davenport (University of North Carolina), examined the role of proactive growth hormone treatment for prevention of growth failure in preschool girls with TS, providing unique data on long-term outcomes of early intervention. In addition to her roles in TS research, Charmian has served as medical advisor to the US Turner syndrome support group and led the development of the section on growth and puberty for the current International Turner Syndrome Clinical Practice Guidelines.
Abstracts this author is presenting: